Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3119.

https://doi.org/10.1182/blood-2024-194561

Published: 2024

Journal Articles

Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Zheng Song, Ying Cheng, Haiyan Yang, Liling Zhang, Liqun Zou, Ye Guo, Junning Cao, Huiqiang Huang, Zhao Wang, Sha Huang, Yiqian Fang, Jiaoyan Lyu, Keshu Zhou, Huilai Zhang

Blood (2024) 144 (Supplement 1): 986.

https://doi.org/10.1182/blood-2024-193167

Published: 2024

Journal Articles

Spatial Multi-Omics Treatment Paradigms in a Phase II Clinical Study of Early Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Meijuan Wu, Xi Chen, Jialiang Lu, Weihao Zhuang, Chang He, Cong Li, Haifeng Yu, Tao Lei, Xiaowu Dong, Jianpeng Sheng, Haiyan Yang

Blood (2024) 144 (Supplement 1): 2996.

https://doi.org/10.1182/blood-2024-203388

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Juying Wei, Wenjuan Yu, Zhengming Jin, Keshu Zhou, Haiyan Yang, Fei Li, Lanfang Li, Bo Zhang, Miao Hu, Yanping Zhang, Xinglu Zhou, Jie Jin

Blood (2024) 144 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2024-201210

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory B-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Juying Wei, Wenjuan Yu, Zhengming Jin, Keshu Zhou, Haiyan Yang, Fei Li, Lanfang Li, Bo Zhang, Miao Hu, Yanping Zhang, Xinglu Zhou, Jie Jin

Blood (2024) 144 (Supplement 1): 3015.

https://doi.org/10.1182/blood-2024-201190

Published: 2024

Journal Articles

Phase 1/2 Studies of DZD8586, a Non-Covalent BBB Penetrant LYN/BTK Dual Inhibitor, in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia (CLL) and Other B-Cell Non-Hodgkin Lymphoma (B-NHL)

Blood (2024) 144 (Supplement 1): 3248.

https://doi.org/10.1182/blood-2024-197877

Published: 2024

Journal Articles

Efficacy and Safety of Bendamustine, Pomalidomide, Sintilimab in Patients with Recurrent or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study

Haiyan Yang, Shengsheng Zhou, Fengxiang Huang, Meiwei Li, Wenguang Bao, Man Wang, Dong Lan, Zhigang Peng

Blood (2024) 144 (Supplement 1): 6519.

https://doi.org/10.1182/blood-2024-204441

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory(R/R)Central Nervous System Lymphoma, Results from the Phase Ia Monotherapy of HZ-a-018-102 Study

Wenbin Li, Zhuang Kang, Feng Chen, Shenglan Li, Xi Chen, Xianggui Yuan, Haiyan Yang, Wenbin Qian, Miao Hu, Yanping Zhang, Xinglu Zhou

Blood (2024) 144 (Supplement 1): 6510.

https://doi.org/10.1182/blood-2024-201137

Published: 2024

Journal Articles

Preclinical Study of a Novel USP28 Inhibitor for the Treatment of Burkitt Lymphoma

Jieyu Xu, Shu Sun, Wen Gao, Pumin Zhang, Haiyan Yang, Honghu Zhu

Blood (2024) 144 (Supplement 1): 5838.

https://doi.org/10.1182/blood-2024-209311

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory (R/R) Central Nervous System Lymphoma or Treatment-Naïve (TN) Central Nervous System Lymphoma, Results from the Phase Ib Combination Part of HZ-a-018-102 Study

Wenbin Li, Zhuang Kang, Feng Chen, Shenglan Li, Xi Chen, Xianggui Yuan, Haiyan Yang, Wenbin Qian, Miao Hu, Yanping Zhang, Xinglu Zhou

Blood (2024) 144 (Supplement 1): 6482.

https://doi.org/10.1182/blood-2024-201166

Published: 2024

Journal Articles

MBS303, a Novel 2:1 CD20×CD3 Bispecific Antibody, Demonstrated a Favorable Safety and Potent Antitumor Activity in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma: Preliminary Results from a Phase Ⅰ, Dose-Escalation Trial

Yuqin Song, Haiyan Yang, Youchao Jia, Lixia Sheng, Lijuan Deng, Xi Chen, Yongjing Tang, Xifang Liu, Sijun Liu, Min Wei, Feng Li

Blood (2024) 144 (Supplement 1): 6481.

https://doi.org/10.1182/blood-2024-199342

Published: 2024

Journal Articles

Effectiveness and Safety of Polatuzumab Vedotin-Based Therapy for Diffuse Large B-Cell Lymphoma: Real-Life Experience from China

Xi Chen, Haifeng Yu, Cong Li, Jieyu Xu, Tao Lei, Shuiyun Han, Shuailing Peng, Haiyan Yang

Blood (2024) 144 (Supplement 1): 7782.

https://doi.org/10.1182/blood-2024-207832

Published: 2024

Journal Articles

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Blood (2024) 144 (Supplement 1): 1635.

https://doi.org/10.1182/blood-2024-194572

Published: 2024

Journal Articles

Novel Combination Regimen Brentuximab Vedotin-Bege Achieves Remarkable Efficacy in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Xi Chen, Huilin Peng, Haifeng Yu, Cong Li, Tao Lei, Shuiyun Han, Shuailing Peng, Haiyan Yang

Blood (2024) 144 (Supplement 1): 6364.

https://doi.org/10.1182/blood-2024-207627

Published: 2024

Journal Articles

A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

Blood (2023) 142 (Supplement 1): 306.

https://doi.org/10.1182/blood-2023-180137

Published: 2023

Journal Articles

PD-1 Blockade Combined with R-CHOP in Patients with Newly Diagnosed EBV-Positive Diffuse Large B-Cell Lymphoma: A Retrospective Analysis

Xi Chen, Yingying Chen, Tao Lei, Haifeng Yu, Cong Li, Yongwei Hong, Haiyan Yang

Blood (2023) 142 (Supplement 1): 4506.

https://doi.org/10.1182/blood-2023-182685

Published: 2023

Journal Articles

Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow up

Yuqin Song, Keshu Zhou, Dengju Li, Jianda Hu, Dehui Zou, Sujun Gao, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Ru Feng, Jie Jin, Fangfang Lyu, Cheng Fang, Sheng Xu, Jun Zhu

Blood (2023) 142 (Supplement 1): 1682.

https://doi.org/10.1182/blood-2023-181352

Published: 2023

Journal Articles

Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2023) 142 (Supplement 1): 4469.

https://doi.org/10.1182/blood-2023-173645

Published: 2023

Journal Articles

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Dual CK1ε/PI3Kδ Inhibitor HZ-H08905 in Adult Patients with Relapsed and/or Refractory Hematologic Malignancies

Juying Wei, Wenjuan Yu, Zhengming Jin, Keshu Zhou, Haiyan Yang, Fei Li, Lanfang Li, Miao Hu, Xinglu Zhou, Jie Jin

Blood (2023) 142 (Supplement 1): 4428.

https://doi.org/10.1182/blood-2023-185363

Published: 2023

Journal Articles

Phase II, Single-Center, Prospective Study of Intrathecal Thiotepa for the Prophylaxis of Secondary Central Nervous System Involvement in Highly Aggressive B-Cell Lymphoma

Cong Li, Tao Lei, Haifeng Yu, Xi Chen, Shuailing Peng, Shuiyun Han, Haiyan Yang

Blood (2023) 142 (Supplement 1): 6227.

https://doi.org/10.1182/blood-2023-184694

Published: 2023

NARROW

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Spatial Multi-Omics Treatment Paradigms in a Phase II Clinical Study of Early Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory B-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Phase 1/2 Studies of DZD8586, a Non-Covalent BBB Penetrant LYN/BTK Dual Inhibitor, in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia (CLL) and Other B-Cell Non-Hodgkin Lymphoma (B-NHL)

Efficacy and Safety of Bendamustine, Pomalidomide, Sintilimab in Patients with Recurrent or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study

Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory(R/R)Central Nervous System Lymphoma, Results from the Phase Ia Monotherapy of HZ-a-018-102 Study

Preclinical Study of a Novel USP28 Inhibitor for the Treatment of Burkitt Lymphoma

Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory (R/R) Central Nervous System Lymphoma or Treatment-Naïve (TN) Central Nervous System Lymphoma, Results from the Phase Ib Combination Part of HZ-a-018-102 Study

MBS303, a Novel 2:1 CD20×CD3 Bispecific Antibody, Demonstrated a Favorable Safety and Potent Antitumor Activity in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma: Preliminary Results from a Phase Ⅰ, Dose-Escalation Trial

Effectiveness and Safety of Polatuzumab Vedotin-Based Therapy for Diffuse Large B-Cell Lymphoma: Real-Life Experience from China

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Novel Combination Regimen Brentuximab Vedotin-Bege Achieves Remarkable Efficacy in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

PD-1 Blockade Combined with R-CHOP in Patients with Newly Diagnosed EBV-Positive Diffuse Large B-Cell Lymphoma: A Retrospective Analysis

Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow up

Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Dual CK1ε/PI3Kδ Inhibitor HZ-H08905 in Adult Patients with Relapsed and/or Refractory Hematologic Malignancies

Phase II, Single-Center, Prospective Study of Intrathecal Thiotepa for the Prophylaxis of Secondary Central Nervous System Involvement in Highly Aggressive B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only